Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of compounds that will prevent tau pathology.

Journal of molecular neuroscience : MN - 1 Dec 2002

Kosik Kenneth S, Ahn Jae, Stein Ross, Yeh Li-An

Abstract excerpt

Tau is certainly a reasonable target for the development of compounds to prevent neurofibrillary pathology, particularly in the fronto-temporal dementias. Although the mechanism of the filamentous accumulations remains unclear, sufficient knowledge is in place to move forward with high throughput screens. In fact, the development of compounds from such screens will ultimately be the only way to validate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase 5
Share to Cyclin-Dependent Kinases
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Nerve Tissue Proteins

Share to Phosphorylation

Share to tau Proteins

Share to Tauopathies

Source

Identifiers

PMID: 12540051
DOI: 10.1385/JMN:19:3:261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of compounds that will prevent tau pathology.PMID 12540051Read ↗

A phenotypic screen for novel small molecules that correct tau-mediated pathologies in human frontotemporal dementia neurons.Semantic proximity Read ↗

Design of Tau Aggregation Inhibitors Using Iterative Machine Learning and a Polymorph-Specific Brain-Seeded Fibril Amplification AssaySemantic proximity Read ↗

De novo designed protein inhibitors of amyloid aggregation and seedingSemantic proximity Read ↗

Structure-based inhibitors halt prion-like seeding by Alzheimer’s disease–and tauopathy–derived brain tissue samplesSemantic proximity Read ↗

In vitro Tau Aggregation Inducer Molecules Influence the Effects of MAPT Mutations on Aggregation Dynamics.Semantic proximity Read ↗

Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau.Semantic proximity Read ↗

Twelve phosphomimetic mutations induce the assembly of recombinant full-length human tau into paired helical filamentsSemantic proximity Read ↗

<i>In vitro</i> tau aggregation inducer molecules influence the effects of <i>MAPT</i> mutations on aggregation dynamicsSemantic proximity Read ↗

Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy.Semantic proximity Read ↗

Twelve phosphomimetic mutations induce the assembly of recombinant full-length human tau into paired helical filaments.Semantic proximity Read ↗

Tau Disaggregation by a CNS-Permeable Small Molecule Reduces Fibril and Oligomer Burden and Preserves Proteostasis and BehaviorSemantic proximity Read ↗

Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.